Centre Hospitalier Universitaire de Liège-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2024

  1. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

    ESMO Open, Vol. 9, Núm. 6

2023

  1. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors

    The oncologist, Vol. 28, Núm. 3, pp. 258-267

  2. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

    Journal of Thoracic Oncology, Vol. 18, Núm. 2, pp. 181-193